EA033446B1 - Гетероциклическое соединение для лечения дегенерации желтого пятна и/или болезни штаргардта - Google Patents

Гетероциклическое соединение для лечения дегенерации желтого пятна и/или болезни штаргардта

Info

Publication number
EA033446B1
EA033446B1 EA201790912A EA201790912A EA033446B1 EA 033446 B1 EA033446 B1 EA 033446B1 EA 201790912 A EA201790912 A EA 201790912A EA 201790912 A EA201790912 A EA 201790912A EA 033446 B1 EA033446 B1 EA 033446B1
Authority
EA
Eurasian Patent Office
Prior art keywords
stargardt
disease
macular degeneration
heterocyclic compound
treating macular
Prior art date
Application number
EA201790912A
Other languages
English (en)
Other versions
EA201790912A1 (ru
Inventor
Yoshihiro Banno
Masahiro Kamaura
Kazuaki Takami
Koichiro Fukuda
Shigekazu Sasaki
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of EA201790912A1 publication Critical patent/EA201790912A1/ru
Publication of EA033446B1 publication Critical patent/EA033446B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/46—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/36—One oxygen atom
    • C07D263/38—One oxygen atom attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Abstract

Предложено гетероциклическое соединение формулы (I), обладающее превосходным RBP4-понижающим действием, которое может быть использовано в качестве лекарственного средства, которое представляет собой профилактическое или терапевтическое средство для лечения дегенерации желтого пятна и/или болезни Штаргардта:где каждый символ имеет значения, определенные в описании, или его соль.
EA201790912A 2014-10-24 2015-10-22 Гетероциклическое соединение для лечения дегенерации желтого пятна и/или болезни штаргардта EA033446B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014217770 2014-10-24
PCT/JP2015/079782 WO2016063933A1 (ja) 2014-10-24 2015-10-22 複素環化合物

Publications (2)

Publication Number Publication Date
EA201790912A1 EA201790912A1 (ru) 2017-09-29
EA033446B1 true EA033446B1 (ru) 2019-10-31

Family

ID=55760964

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790912A EA033446B1 (ru) 2014-10-24 2015-10-22 Гетероциклическое соединение для лечения дегенерации желтого пятна и/или болезни штаргардта

Country Status (37)

Country Link
US (4) US10214498B2 (ru)
EP (2) EP3210973B1 (ru)
JP (2) JP6588027B2 (ru)
KR (1) KR102490156B1 (ru)
CN (2) CN115197160A (ru)
AR (1) AR104342A1 (ru)
AU (2) AU2015336480B2 (ru)
BR (1) BR112017007138A2 (ru)
CA (1) CA2965465C (ru)
CL (1) CL2017000944A1 (ru)
CO (1) CO2017003699A2 (ru)
CR (1) CR20170160A (ru)
CY (1) CY1123842T1 (ru)
DK (1) DK3210973T3 (ru)
DO (1) DOP2017000098A (ru)
EA (1) EA033446B1 (ru)
EC (1) ECSP17026687A (ru)
ES (1) ES2848999T3 (ru)
HR (1) HRP20210320T1 (ru)
HU (1) HUE053443T2 (ru)
IL (2) IL285105B2 (ru)
LT (1) LT3210973T (ru)
MA (2) MA39688B1 (ru)
MX (2) MX2017004629A (ru)
MY (1) MY183209A (ru)
PE (1) PE20170669A1 (ru)
PH (1) PH12017500747A1 (ru)
PL (1) PL3210973T3 (ru)
PT (1) PT3210973T (ru)
RS (1) RS61504B1 (ru)
SG (1) SG11201702312UA (ru)
SI (1) SI3210973T1 (ru)
TN (1) TN2017000097A1 (ru)
TW (2) TWI703131B (ru)
UA (1) UA121871C2 (ru)
WO (1) WO2016063933A1 (ru)
ZA (1) ZA201703344B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY183209A (en) 2014-10-24 2021-02-18 Takeda Pharmaceuticals Co Heterocyclic compound
AU2018240031B2 (en) 2017-03-20 2022-07-14 President And Fellows Of Harvard College Compounds and methods for the treatment of parasitic diseases
CN112512521A (zh) * 2018-08-01 2021-03-16 纽约市哥伦比亚大学理事会 用于治疗和预防非酒精性脂肪肝疾病和痛风的rbp4拮抗剂
CN111690698A (zh) * 2020-05-19 2020-09-22 浙江工业大学 两步串联流动合成3-（苯并[d][1,3]二氧-5-氨基）丙羟肟酸的方法
CN111690695A (zh) * 2020-05-19 2020-09-22 浙江工业大学 3-苯氨基丙羟肟酸的酶促微流控在线合成方法
WO2022256301A1 (en) * 2021-06-01 2022-12-08 Stargazer Pharmaceuticals, Inc. Methods and compounds for treating subjects with stargardt disease

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009051244A1 (ja) * 2007-10-18 2009-04-23 Takeda Pharmaceutical Company Limited 複素環化合物
WO2009145286A1 (ja) * 2008-05-30 2009-12-03 武田薬品工業株式会社 複素環化合物
JP2010540541A (ja) * 2007-09-27 2010-12-24 リヴィジョン セラピューティクス，インク． レチノール関連疾患を治療するための方法及び化合物
JP2012523461A (ja) * 2009-04-13 2012-10-04 アイアールエム・リミテッド・ライアビリティ・カンパニー レチノール結合タンパク質４（ｒｂｐ４）へのレチノールの結合を調節するための組成物および方法
JP2012524024A (ja) * 2009-04-16 2012-10-11 武田薬品工業株式会社 （とりわけ）糖尿病の予防または治療に有用なｎ−アシル−ｎ’−フェニルピペラジンの誘導体

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625970A (en) 1968-04-17 1971-12-07 Cutter Lab 1-(disubstituted phenyl or benzyl)-1h-indazol-3-yloxyacetic acid
US5239080A (en) 1989-02-08 1993-08-24 Takeda Chemical Industries, Ltd. Oxazole compounds and their use as antidiabetic and bone-reduction inhibitory agents
EP0440183A1 (en) * 1990-02-01 1991-08-07 Takeda Chemical Industries, Ltd. Oxazole compounds, their production and use
US6025372A (en) 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
WO1999022735A1 (en) 1997-10-30 1999-05-14 Merck & Co., Inc. Somatostatin agonists
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
WO2001025228A1 (fr) 1999-10-07 2001-04-12 Tadeka Chemical Industries, Ltd. Derives d'amines
MXPA02004647A (es) 1999-11-10 2002-10-31 Takeda Chemical Industries Ltd Compuestos heterociclicos de 5 miembros que contienen nitrogeno.
GB0020351D0 (en) 2000-08-17 2000-10-04 Catalyst Biomedica Ltd Treatment of hyperproliferative diseases
DE10149568A1 (de) * 2001-10-08 2003-04-24 Consequence Gmbh Verfahren zur Sequenzanalyse von Polypeptiden
WO2003042204A1 (fr) 2001-10-19 2003-05-22 Takeda Chemical Industries, Ltd. Derive d'amine
US20040214788A1 (en) 2003-03-11 2004-10-28 Raj Madhwa H.G. Treatment of prostate cancer
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
ES2278346T3 (es) 2003-08-20 2007-08-01 Eli Lilly And Company Compuestos, procedimientos y formulaciones para suministro oral de un compuesto peptido (glp)-1 del tipo de glucagon o un peptido agonista (glp)-4 del receptor 4 de melacortina (mc4).
JP4869942B2 (ja) 2003-12-11 2012-02-08 ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド インスリン感受性／抵抗性、糖尿病および肥満におけるｒｂｐ４
US7838561B2 (en) 2004-06-14 2010-11-23 Wisconsin Alumni Research Foundation Method for preventing or treating cardiac hypertrophy
AU2005262558B8 (en) 2004-06-23 2008-04-10 Revision Therapeutics, Inc. Methods and compositions for treating ophthalmic conditions with retinyl derivatives
JP2008507557A (ja) 2004-07-22 2008-03-13 ヴァンダ ファーマシューティカルズ インコーポレイテッド 眼疾患の治療法
US7947267B2 (en) 2004-10-08 2011-05-24 Potentia Pharmaceuticals, Inc. Viral complement control proteins for eye disorders
KR20090029814A (ko) 2006-06-22 2009-03-23 시리온 테라퓨틱스, 인크. 메갈린 활성의 조절을 통한 안질환의 치료 방법 및 조성물
AU2008268409B2 (en) 2007-06-26 2013-12-05 Lexicon Pharmaceuticals, Inc. Compositions comprising tryptophan hydroxylase inhibitors
BRPI0813212A2 (pt) 2007-06-26 2014-12-23 Lexicon Pharmaceuticals Inc Métodos de tratamento de doenças e distúrbios mediados por serotonina
US7973079B2 (en) 2007-09-27 2011-07-05 Revision Therapeutics, Inc. Methods and compounds for treating retinol-related diseases
US8541388B2 (en) 2008-05-22 2013-09-24 Isis Pharmaceuticals, Inc. Methods for modulating expression of RBP4
JP2013509430A (ja) 2009-10-28 2013-03-14 リヴィジョン セラピューティクス，インク． レチンアミドによる皮膚癌の予防
WO2011072275A2 (en) 2009-12-11 2011-06-16 Nono, Inc. Agents and methods for treating ischemic and other diseases
EP2560966B1 (en) 2010-03-30 2021-01-06 Verseon International Corporation Multisubstituted aromatic compounds as inhibitors of thrombin
US8980924B2 (en) 2010-11-24 2015-03-17 The Trustees Of Columbia University In The City Of New York Non-retinoid RBP4 antagonist for treatment of age-related macular degeneration and stargardt disease
US9556166B2 (en) 2011-05-12 2017-01-31 Proteostasis Therapeutics, Inc. Proteostasis regulators
GB201205679D0 (en) 2012-03-30 2012-05-16 Dyson Technology Ltd A hand held appliance
WO2013166041A1 (en) 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York Transthyretin ligands capable of inhibiting retinol-dependent rbp4-ttr interaction for treatment of age-related macular
WO2014134127A1 (en) 2013-02-26 2014-09-04 Northeastern University Cannabinergic nitrate esters and related analogs
WO2014160409A1 (en) 2013-03-14 2014-10-02 The Trustees Of Columbia University In The City Of New York Rbp4 antagonists for the treatment of age-related macular degeneration and stargardt disease
WO2014153643A1 (en) 2013-03-26 2014-10-02 The University Of British Columbia Compositions and methods for use thereof in the treatment of aniridia
AU2015226881A1 (en) 2014-03-07 2016-09-29 Intonation Research Laboratories Inhibitors of histone lysine specific demethylase (LSD1) and histone deacetylases (HDACs)
EP3209656B1 (en) 2014-10-24 2020-04-01 Bristol-Myers Squibb Company Indole carboxamides compounds useful as kinase inhibitors
MY183209A (en) * 2014-10-24 2021-02-18 Takeda Pharmaceuticals Co Heterocyclic compound
SG10201903619YA (en) 2014-10-24 2019-05-30 Bristol Myers Squibb Co Carbazole derivatives
US11040976B2 (en) 2015-04-24 2021-06-22 President And Fellows Of Harvard College Substrate selective inhibitors of insulin-degrading enzyme (IDE) and uses thereof
US10189797B2 (en) 2015-12-30 2019-01-29 Duke University Chemical modulators of immune checkpoints and therapeutic use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010540541A (ja) * 2007-09-27 2010-12-24 リヴィジョン セラピューティクス，インク． レチノール関連疾患を治療するための方法及び化合物
WO2009051244A1 (ja) * 2007-10-18 2009-04-23 Takeda Pharmaceutical Company Limited 複素環化合物
WO2009145286A1 (ja) * 2008-05-30 2009-12-03 武田薬品工業株式会社 複素環化合物
JP2012523461A (ja) * 2009-04-13 2012-10-04 アイアールエム・リミテッド・ライアビリティ・カンパニー レチノール結合タンパク質４（ｒｂｐ４）へのレチノールの結合を調節するための組成物および方法
JP2012524024A (ja) * 2009-04-16 2012-10-11 武田薬品工業株式会社 （とりわけ）糖尿病の予防または治療に有用なｎ−アシル−ｎ’−フェニルピペラジンの誘導体

Also Published As

Publication number Publication date
PH12017500747B1 (en) 2017-10-30
IL251695A0 (en) 2017-06-29
AU2020204426B2 (en) 2022-02-03
CA2965465C (en) 2023-08-01
CN115197160A (zh) 2022-10-18
BR112017007138A2 (pt) 2017-12-26
TN2017000097A1 (en) 2018-07-04
IL285105A (en) 2021-08-31
EP3848353A1 (en) 2021-07-14
EP3210973A1 (en) 2017-08-30
WO2016063933A1 (ja) 2016-04-28
US20210340114A1 (en) 2021-11-04
PL3210973T3 (pl) 2021-06-28
CN107108506B (zh) 2022-06-21
PE20170669A1 (es) 2017-06-06
IL285105B2 (en) 2023-03-01
MA53568A (fr) 2022-02-23
CN107108506A (zh) 2017-08-29
HUE053443T2 (hu) 2021-06-28
JPWO2016063933A1 (ja) 2017-08-03
DK3210973T3 (da) 2021-02-08
MX2017004629A (es) 2017-06-30
JP6995094B2 (ja) 2022-02-21
SI3210973T1 (sl) 2021-04-30
US20190119225A1 (en) 2019-04-25
CA2965465A1 (en) 2016-04-28
TWI749661B (zh) 2021-12-11
ES2848999T3 (es) 2021-08-13
EP3210973B1 (en) 2020-12-02
US20200157062A1 (en) 2020-05-21
CL2017000944A1 (es) 2018-01-12
TW201714876A (zh) 2017-05-01
DOP2017000098A (es) 2017-07-15
AU2015336480A2 (en) 2017-06-01
RS61504B1 (sr) 2021-03-31
CO2017003699A2 (es) 2017-07-28
US20180237404A1 (en) 2018-08-23
KR20170067791A (ko) 2017-06-16
PT3210973T (pt) 2021-02-12
EA201790912A1 (ru) 2017-09-29
MX2021001188A (es) 2021-04-19
IL285105B (en) 2022-11-01
AR104342A1 (es) 2017-07-12
AU2015336480B2 (en) 2020-04-02
UA121871C2 (uk) 2020-08-10
EP3210973A4 (en) 2018-04-25
US10544111B2 (en) 2020-01-28
KR102490156B1 (ko) 2023-01-18
TWI703131B (zh) 2020-09-01
ECSP17026687A (es) 2017-09-29
CR20170160A (es) 2017-06-15
MY183209A (en) 2021-02-18
TW202042805A (zh) 2020-12-01
IL251695B (en) 2021-08-31
LT3210973T (lt) 2021-03-25
MA39688B1 (fr) 2021-02-26
ZA201703344B (en) 2018-08-29
HRP20210320T1 (hr) 2021-04-30
JP6588027B2 (ja) 2019-10-09
AU2015336480A1 (en) 2017-05-25
MA39688A (fr) 2017-08-30
AU2020204426A1 (en) 2020-07-23
CY1123842T1 (el) 2022-05-27
SG11201702312UA (en) 2017-05-30
JP2020007347A (ja) 2020-01-16
US10214498B2 (en) 2019-02-26
US10975043B2 (en) 2021-04-13
PH12017500747A1 (en) 2017-10-30

Similar Documents

Publication Publication Date Title
ZA201701299B (en) Glycosidase inhibitors
EA033446B1 (ru) Гетероциклическое соединение для лечения дегенерации желтого пятна и/или болезни штаргардта
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
MY192055A (en) Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
MX2015009444A (es) Trampas novedosas en el tratamiento de la degeneracion macular.
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
PH12016502352A1 (en) Pharmaceutical composition
SA517381678B1 (ar) مركبات داي هيدرو بيريميدين-2-أون واستخدامها الطبي
WO2016004413A3 (en) Gls1 inhibitors for treating disease
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
EA032654B9 (ru) [1,2,4]ТРИАЗОЛО[4,3-b]ПИРИДАЗИНЫ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
ZA202200511B (en) Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
EP3549582A3 (en) Novel capsazepine analogs for the treatment of cancer and other proliferative diseases
WO2019040105A3 (en) COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES
MY198753A (en) Treatment of androgen deprivation therapy associated symptoms
IL248428A0 (en) Use of 3,1-propanedisulfonic acid or pharmaceutically acceptable saline to treat sarcoidosis
IL260009B (en) Novel bicyclic-compounds for use as a medicament, in particular for treatment of parkinson's disease
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases
EP3094330A4 (en) Treatment of crohn's disease using low doses of laquinimod
GB2546703A (en) Compounds
MA39718A (fr) Compositions et méthodes d'utilisation de celles-ci